Project Description

Μελος ΔΕΠ / Τομέας Γενετικής Βιολογίας Κυττάρου & Ανάπτυξης
Βαθμίδα: Επίκουρη Καθηγήτρια
Γραφείο: 2ος Όροφος
Email: gkallergi@upatras.gr, kalergi@med.uoc.gr
Τηλέφωνο: 2610 969248
Αναφορές: Eρευνητικός κόμβος για το Πανεπιστήμιο Πατρών του European Liquid Biopsy Society

Επιστημονική κατάρτιση

  • 1995 Πτυχίο Βιολογίας, Τμήμα Βιολογικό, Πανεπιστήμιο Πατρών.
  • 1997 Μεταπτυχιακό δίπλωμα ειδίκευσης, Τμήμα Βιολογίας, Πανεπιστήμιο Κρήτης.
  • 2003 Διδακτορικό δίπλωμα, Ιατρική Σχολή, Πανεπιστήμιο Κρήτης.
  • 2003-2006 Mεταδιδακτορική έρευνα Εργαστήριο Βιοχημείας, Τμήμα Ιατρικής, Πανεπιστήμιο Κρήτης.
  • 2006-2015 Μεταδιδακτορική έρευνα Εργαστήριο Βιολογίας του Καρκίνου, Ιατρική Σχολή Πανεπιστήμιο Κρήτης.
  • 2015 Διακρατική συνεργασία-Επισκέπτης ερευνητής: The microtubule, signal transduction lab, Weill Cornell Medical College, Division of Hematology & Medical Oncology. Επισκέπτης ερευνητής: Marlene and Stewart Greenebaum NCI Cancer Center, University of Maryland School of Medicine.

Εκπαιδευτικές δραστηριότητες

Διδασκαλία Μαθημάτων

  • Βιοχημεία Ι,
  • Βιοχημεία ΙΙ

Ερευνητικές και άλλες δραστηριότητες

  • Διερεύνηση νέων σηματοδοτικών μονοπατιών στα καρκινικά κύτταρα σχετιζόμενα με την μεταστατική διαδικασία.
  • Ανίχνευση και χαρακτηρισμός των κυκλοφορούντων καρκινικών κυττάρων (CTCs) στο αίμα ασθενών με καρκίνο.
  • Ανάπτυξη νέων διαγνωστικών εργαλείων υγρής βιοψίας για ασθενείς με καρκίνο του μαστού, προστάτη και πνεύμονα.
  • Μελέτη της μικρομεταστατικής νόσου στο μυελό των οστών ασθενών με καρκίνο.
  • Διερεύνηση της αλληλεπίδρασης των καρκινικών κυττάρων με το μικροπεριβάλλον του όγκου και τα κύτταρα του ανοσοποιητικού.
  • Ανάπτυξη νέων μεθόδων 3D καλλιέργειας των καρκινικών κυττάρων.

Ενεργά ερευνητικά προγράμματα:

  • ΕΣΠΑ 2017, ΕΡΕΥΝΩ-ΔΗΜΙΟΥΡΓΩ-ΚΑΙΝΟΤΟΜΩ: Ρομποτικό μικροσκόπιο οδηγούμενο από υπερφασματική όραση.
  • ΕΣΠΑ 2019, ΕΡΕΥΝΩ-ΔΗΜΙΟΥΡΓΩ-ΚΑΙΝΟΤΟΜΩ: Ανάπτυξη καινοτόμων διαγνωστικών εργαλείων για ανίχνευση και χαρακτηρισμό Kυκλοφορούντων Kαρκινικών Kυττάρων (ΚΚΚ) στο αίμα των ασθενών.
  • Διακρατική συνεργασία με το πανεπιστήμιο King Saud University: The novel oncogene KDM2B in the epigenetic regulation of the cytoskeleton.

Αντιπροσωπευτικές Δημοσιεύσεις

  • Kallergi, O. Hoffmann, AK. Bittner, L. Papadimitriou, N Zacharopoulou, M. Zervakis, S. Sfakianakis, C. Stournaras, V. Georgoulias, R. Kimmig, S. Kasimir-Bauer. CXCR4 and JUNB double positive disseminated tumor cells are frequently detected in breast cancer patients at primary diagnosis (Under press in Therapeutic Advances in Medical Oncology)
  • Kallergi, V. Tsintari, S Sfakianakis, E.S. Bei, N. Zacharopoulou, C. Stournaras, M. Zervakis and V. Georgoulias The prognostic value of JUNB-positive CTCs in metastatic breast cancer; from bioinformatics to immunophenotype. Breast Cancer Res. 2019 Aug 1;21(1):86..
  • Kotsakis, G. Kallergi, D. Agouraki, Lyristi, Zaharoula, E. Lagoudaki, A. Koutsopoulos, V. Georgoulias E.K. Vetsika,. CD8+PD-1+T cells and PD-L-1+ CTCs in chemotherapy naïve NSCLC: Towards their clinical relevance Ther Adv Med Oncol. 2019 Jun 12;11
  • Kallergi, D. Aggouraki, N. Zacharopoulou, C. Stournaras, V. Georgoulias, S.S. Martin. Evaluation of microtentacles on Circulating Tumor Cells (CTCs); Interaction between CTCs and blood cells through cytoskeletal proteins. Breast Cancer Res. 2018 Jul 5;20(1):67.
  • Zacharopoulou, A. Tsapara, G. Kallergi, E. Schmid, S. Alkahtani, , S. C. Kampranis, and Ch. Stournaras. The epigenetic factor KDM2B regulates EMT and small GTPases in colon tumor cells. Cell Physiol Biochem, 2018 May 14;47(1):368-377
  • Kallergi, E.K. Vetsika, D. Agouraki, E. Lagoudaki, A. Koutsopoulos, F. Koinis , P. Katsarlinos, M. Trypaki, I. Messaritakis, C. Stournaras, V. Georgoulias, A. Kotsakis. Evaluation of PD-L1/PD-1 on Circulating Tumor Cells (CTCs) in patients with advanced non-small cell lung cancer (NSCLC). Therapeutic Advances in Medical Oncology Journal, 2018 Jan 15;10
  • Zacharopoulou, A.Tsapara, G.Kallergi, E. Schmid, P.N. Tsichlis, S. C Kampranis& C. Stournaras RhoA/B-GTPases-governed actin cytoskeleton signaling regulates KDM2B-induced motility in prostate cancer cells Biochim Biophys Acta. 2018 Apr;1865(4):587-597.
  • Politaki, S. Agelaki, S. Apostolaki, D. Hatzidaki, Areti Strati, F. Koinis, M. Perraki, G. Saloustrou, G. Stoupis, G. Kallergi, M. Spiliotaki, T. Skaltsi, E. Lianidou, V. Georgoulias, D. Mavroudis.A comparison of three methods for the detection of circulating tumor cells in patients with early and metastatic breast cancer. Cell Physiol Biochem, 2017;44(2):594-606.
  • J. Stagno, A. Tsapara, N. Zacharopoulou, J. Bochem, L. Pelzl, T. Maghout, G. Kallergi, S. Alkahtani, K. Alevizopoulos, K. Dimas, T. Calogeropoulou, S. W. Warmann, F. Lang, E. Schmid, Ch. Stournaras. Istaroxime inhibits motility and down-regulates Orai1 expression, SOCE and FAK phosphorylation in prostate cancer cells. Cell Physiol Biochem. 2017 Jul 14;42(4):1366-1376.
  • Messaritakis, E. Politaki, A. Kotsakis, K. Dermitzaki, P. Koinis, E. Lagoudaki, A. Koutsopoulos, G. Kallergi, J. Souglakos, V. Georgoulias. Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer (SCLC). PLoS One. 2017 Jul 18;12(7)
  • Spiliotaki, D. Mavroudis, M. Kokotsaki, E. K. Vetsika, I Stoupis, A. Matikas, G. Kallergi, V. Georgoulias, S. Agelaki. Insulin-like growth factor-1 receptor expression in circulating tumor cells of patients with breast cancer is associated with E-cadherin expression and patients’ outcome (Mol Oncol. 2017 Aug 2doi: 10.1002/1878-0261.12114.)
  • Agelaki, Melina Dragolia, H. Markonanolaki, S. Alkahtani, Ch. Stournaras, V. Georgoulias, G. Kallergi, Phenotypic characterization of circulating tumor cells (CTCs) in triple negative breast cancer patients (TNBC), Oncotarget 2017 Jan 17;8(3):5309-5322
  • Kallergi, E. Politaki, S. Alkahtani, C. Stournaras, V. Georgoulias. Evaluation of Isolation methods for Circulating Tumor Cells. Cell Physiol Biochem. 2016;40(3-4):411-419.
  • Kallergi, S. Agelaki, M. A. Papadaki, D. Nasias, A. Matikas, D. Mavroudis, V.Georgoulias. Expression of truncated HER2 receptor (p95HER2) in Circulating Tumor Cells (CTCs) of breast cancer patients. Breast Cancer Res. 2015 Aug 19;17:113.
  • Agelaki S, Kalykaki A, Markomanolaki H, Papadaki MA, Kallergi G, Hatzidaki D, Kalbakis K, Mavroudis D, Georgoulias. Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer. PLoS One. 2015 Jun 17;10(6)
  • M Spiliotaki, D Mavroudis, K Kapranou, H Markomanolaki, G Kallergi, Filippos Koinis, Kostas Kalbakis, Vassilis Georgoulias, Sofia Agelaki Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy. Breast Cancer Res. 2014 Nov 29;16(6):485.
  • *G Kallergi, M.A.Papadaki Z Zafeiriou, L Manouras, P.A. Theodoropoulos, D Mavroudis, V Georgoulias, S Agelaki. Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer. BMC Cancer. 2014 Sep 3; 14:651.
  • A Kalykaki, S Agelaki, G Kallergi, A Xyrafas, D Mavroudis, V Georgoulias. Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib. Cancer Chemother Pharmacol. 2014 Apr;73(4):685-93.
  • G Kallergi, M. Chimonidou, E. Stathopoulos, V. Georgoulias, D. Welch and E. S. Lianidou. Prognostic significance of BRMS1 promoter methylation in operable breast cancer Mol Cancer Res. 2013 Oct;11(10):1248-57
  • *G. Kallergi, G. Konstantinidis, H.Markomanolaki, M. A. Papadaki, D. Mavroudis, C. Stournaras, V. Georgoulias, S. Agelaki Apoptotic Circulating Tumor Cells (CTCs) in early and metastatic breast cancer patients Mol Cancer Ther. 2013 Sep;12(9):1886-95
  • V Georgoulias, V Bozionelou, S Agelaki, M Perraki, S Apostolaki, G Kallergi, K Kalbakis, A Xyrafas, D Mavroudis. Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK19 mRNA-positive circulating tumor cells: results of a randomized phase II study.Ann Oncol. 2012 Feb 29.
  • Kallergi, M. A. Papadaki, E. Politaki, D. Mavroudis, V. Georgoulias, S. Agelaki, Epithelial-Mesenchymal Transition markers expressed in CTCs of early and metastatic breast cancer patients Breast Cancer Res. 2011 10;13(3):R59.
  • Saloustros, M. Perraki, S. Apostolaki, G. Kallergi, K. Kalbakis, S. Agelaki, N. Vardakis, A. Kalykaki, A. Xyrafas, V. GeorgouliasD. Mavroudis Cytokeratin-19 mRNA-positive circulating tumor cells during follow up of patients with early breast cancer: prognostic relevance for late relapse. Breast Cancer Res. 2011 10;13(3):R60
  • Kallergi, Η Markomanolaki, V. Giannoukaraki, M. A. Papadaki, A. Strati, E. Lianidou, V. Georgoulias D. Mavroudis, S. Agelaki. Hypoxia Inducible Factor 1 alpha (HIF-1α) and Vascular endothelial growth factor (VEGF) expression in CTCs of breast cancer patients. (2009) Breast Cancer Res 11(6):R84.
  • PA Theodoropoulos, H Polioudaki, S Agelaki, G Kallergi, Z Saridaki, D Mavroudis, V Georgoulias. (2009) Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett. 1;288(1):99-106.
  • S Agelaki.,. M Spiliotaki  ,. Ch Markomanolaki, G Kallergi., D Mavroudis, V Georgoulias. and C. Stournaras (2009). Caveolin-1 regulates EGFR signalling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition. Cancer Biol Ther. Aug;8(15):1470-7.
  • Papadopoulou N, Papakonstanti EA, Kallergi G, Alevizopoulos K, Stournaras C. (2009). Membrane androgen receptor activation in prostate and breast tumor cells: molecular signaling and clinical impact. IUBMB Life, Jan;61(1):56-61. Review.
  • Apostolaki S, Perraki M, Kallergi G, Kafousi M, Papadopoulos S, Kotsakis A, Pallis A, Xenidis N, Kalmanti L, Kalbakis K, Agelaki S, Kalykaki A, Stournaras C, Stathopoulos E, Georgoulias V, Mavroudis D. (2008). Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance. Breast Cancer Res Treat. Nov 19.
  • Kallergi G, Agelaki S., Kalykaki A., Stournaras C., Mavroudis, D. Georgoulias V. (2008) Phosphorylated EGFR and PI-3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients Breast Cancer Res.;10(5):R80. Highly accessed
  • M Ιgnatiadis, G Kallergi, M Ntoulia, M Perraki, S Apostolaki, M Kafousi, G Chlouverakis, E Stathopoulos, E Lianidou, V Georgoulias, D Mavroudis. (2008) Prognostic Value of the Molecular Detection of Circulating Tumor Cells Using a Multimarker Reverse Transcription-PCR Assay for Cytokeratin 19, Mammaglobin A, and HER2 in Early Breast.  Cancer. Clin Cancer Res. 14(9):2593-600
  • G.Kallergi, S Agelaki, H Markomanolaki, V Georgoulias, C Stournaras.(2007) Activation of FAK/PI3K/Rac1 signaling controls actin reorganization and inhibits cell motility in human cancer cells Cell. Phys. Biochem. Cell Physiol Biochem. 20(6):977-86.
  • G.Kallergi, D Mavroudis, V. Georgoulias and C. Stournaras (2007) Phosphorylation of FAK, PI-3K, and Impaired Actin Organization in CK-positive Micrometastatic Breast Cancer Cells. Mol. Med. 13: 79-88
  • G Kallergi, A Tsapara, M Kampa, EA Papakonstanti, K Krasagakis, E Castanas, C Stournaras (2003) Distinct signaling pathways regulate differential opioid effects on actin cytoskeleton in malignant MCF7 and nonmalignant MCF12A human breast epithelial cells. Exp Cell Res. 288:94-109
  • DA Spandidos, DN Dokianakis, G Kallergi, E. Aggelakis (2000) Molecular basis of gynecological cancer Ann New York Acad Sci. 900:56-64